| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special Articles |
Department of Medicine (I.M.C., M.L.H., S.S.P., M.O.T), Division of Endocrinology and Metabolism, University of Virginia Health Sciences Center; Division of Biostatistics (F.E.H.) and Epidemiology, Department of Health Evaluation Sciences, University of Virginia, Charlottesville, Virginia 22908; Department of Pediatrics (R.L.H.), Stanford University Medical Center, Stanford, California 94305; and Department of Medicine (K.G.M.M.A.), University of Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom NEZ 4HH
Address all correspondence and requests for reprints to: Dr. Michael O. Thorner, Dept of Medicine, Box 466, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908.
To determine the effect of aging on the suppression of GH secretion by insulin-like growth factor (IGF)-I, we studied 11 healthy young adults (6 men, 5 women, mean ± SD: 25.2 ± 4.6 yr old; body mass index 23.7 ± 1.8 kg/m2) and 11 older adults (6 men, 5 women, 69.5 ± 5.8 yr old; body mass index 24.2 ± 2.5 kg/m2). Saline (control) or recombinant human IGF-I (rhIGF-I) (2 h baseline then, in sequence, 2.5 h each of 1, 3, and 10 µg/kg·h) was infused iv during the last 9.5 h of a 40.5-h fast; serum glucose was clamped within 15% of baseline. Baseline serum GH concentrations (mean ± SE: 3.3 ± 0.7 vs. 1.9 ± 0.5 µg/L, P = 0.02) and total IGF-I concentrations (219 ± 15 vs. 103 ± 19 µg/L, P < 0.01) were higher in the younger subjects. In both age groups, GH concentrations were significantly decreased by 3 and 10 µg/kg·h, but not by 1 µg/kg·h rhIGF-I. The absolute decrease in GH concentrations was greater in young than in older subjects during the 3 and 10 µg/kg·h rhIGF-I infusion periods, but both young and older subjects suppressed to a similar GH level during the last hour of the rhIGF-I infusion (0.78 ± 0.24 µg/L and 0.61 ± 0.16 µg/L, respectively). The older subjects had a greater increase above baseline in serum concentrations of both total (306 ± 24 vs. 244 ± 14 µg/L, P = 0.04) and free IGF-I (8.5 ± 1.4 vs. 4.2 ± 0.6 µg/L, P = 0.01) than the young subjects during rhIGF-I infusion, and their GH suppression expressed in relation to increases in both total and free serum IGF-I concentrations was significantly less than in the young subjects. We conclude that the ability of exogenous rhIGF-I to suppress serum GH concentrations declines with increasing age. This suggests that increased sensitivity to endogenous IGF-I negative feedback is not a cause of the decline in GH secretion that occurs with aging.
This article has been cited by other articles:
 |
|
 |
|
  J. D. Veldhuis, D. M. Keenan, J. N. Bailey, A. Adeniji, J. M. Miles, R. Paulo, M. Cosma, and C. Soares-Welch Estradiol Supplementation in Postmenopausal Women Attenuates Suppression of Pulsatile Growth Hormone Secretion by Recombinant Human Insulin-like Growth Factor Type I J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4471 - 4478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. S. Frutos, L. Cacicedo, C. F. Mendez, D. Vicent, M. Gonzalez, and F. Sanchez-Franco Pituitary Alterations Involved in the Decline of Growth Hormone Gene Expression in the Pituitary of Aging Rats J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2007; 62(6): 585 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers Endocrine Control of Body Composition in Infancy, Childhood, and Puberty Endocr. Rev., February 1, 2005; 26(1): 114 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Veldhuis, J. Y. Weltman, A. L. Weltman, A. Iranmanesh, E. E. Muller, and C. Y. Bowers Age and Secretagogue Type Jointly Determine Dynamic Growth Hormone Responses to Exogenous Insulin-Like Growth Factor-Negative Feedback in Healthy Men J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5542 - 5548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yuen, J. Frystyk, M. Umpleby, L. Fryklund, and D. Dunger Changes in Free Rather Than Total Insulin-Like Growth Factor-I Enhance Insulin Sensitivity and Suppress Endogenous Peak Growth Hormone (GH) Release following Short-Term Low-Dose GH Administration in Young Healthy Adults J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3956 - 3964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nass, S. S. Pezzoli, I. M. Chapman, J. Patrie, R. L. Hintz, M. L. Hartman, and M. O. Thorner IGF-I does not affect the net increase in GH release in response to arginine Am J Physiol Endocrinol Metab, October 1, 2002; 283(4): E702 - E710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Anderson, L. Wideman, J. T. Patrie, A. Weltman, C. Y. Bowers, and J. D. Veldhuis E2 Supplementation Selectively Relieves GH's Autonegative Feedback on GH-Releasing Peptide-2-Stimulated GH Secretion J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5904 - 5911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Clasey, A. Weltman, J. Patrie, J. Y. Weltman, S. Pezzoli, C. Bouchard, M. O. Thorner, and M. L. Hartman Abdominal Visceral Fat and Fasting Insulin Are Important Predictors of 24-Hour GH Release Independent of Age, Gender, and Other Physiological Factors J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3845 - 3852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Veldhuis, M. Bidlingmaier, S. M. Anderson, Z. Wu, and C. J. Strasburger Lowering Total Plasma Insulin-Like Growth Factor I Concentrations by Way of a Novel, Potent, and Selective Growth Hormone (GH) Receptor Antagonist, Pegvisomant (B2036-Peg), Augments the Amplitude of GH Secretory Bursts and Elevates Basal/Nonpulsatile GH Release in Healthy Women and Men J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3304 - 3310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Kanaley, J. Y. Weltman, K. S. Pieper, A. Weltman, and M. L. Hartman Cortisol and Growth Hormone Responses to Exercise at Different Times of Day J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2881 - 2889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O. Thorner, C. J. Strasburger, Z. Wu, M. Straume, M. Bidlingmaier, S. S. Pezzoli, K. Zib, J. C. Scarlett, and W. F. Bennett Growth Hormone (GH) Receptor Blockade with a PEG-Modified GH (B2036-PEG) Lowers Serum Insulin-Like Growth Factor-I but Does Not Acutely Stimulate Serum GH J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2098 - 2103. [Abstract] [Full Text]
|
|
|
|
|
|
E. Ghigo, L. Gianotti, E. Arvat, J. Ramunni, M. R. Valetto, F. Broglio, M. Rolla, F. Cavagnini, and E. E. Müller Effects of Recombinant Human Insulin-Like Growth Factor I Administration on Growth Hormone (GH) Secretion, Both Spontaneous and Stimulated by GH-Releasing Hormone or Hexarelin, a Peptidyl GH Secretagogue, in Humans J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 285 - 290. [Abstract] [Full Text]
|
|
|
|
|
|
A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]
|
|
|
|
|
|
I. M. Chapman, M. L. Hartman, K. S. Pieper, E. H. Skiles, S. S. Pezzoli, R. L. Hintz, and M. O. Thorner Recovery of Growth Hormone Release from Suppression by Exogenous Insulin-Like Growth Factor I (IGF-I): Evidence for a Suppressive Action of Free Rather Than Bound IGF-I J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2836 - 2842. [Abstract] [Full Text]
|
|
|
|
|
|
M. E. Wilson Regulation of the Growth Hormone-Insulin-Like Growth Factor I Axis in Developing and Adult Monkeys Is Affected by Estradiol Replacement and Supplementation with Insulin-Like Growth Factor I J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2018 - 2028. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
